Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
|Webcasts|November 17, 2022
How CROs Are Leveraging Innovation to Accelerate Clinical Trials
Author(s)Oracle
November 17th 2022 9 am CT |10 am ET | 3 pm BST | 4 pm CET Faced with an increasingly more competitive future CROs are spearheading of adoption of modern clinical applications to increase efficiency, enhance collaboration, and improve trial performance. Advancements in clinical trial processes have arisen as a result of cross-company collaborations amongst CROs and various industry stakeholders – constrained by time and compelled by regulatory compliance – to support broader industry-wide adoption of innovations.
Register Free:
Event Overview:
Faced with an increasingly more competitive future, CROs are spearheading of adoption of modern clinical applications to increase efficiency, enhance collaboration, and improve trial performance. Advancements in clinical trial processes have arisen as a result of cross-company collaborations amongst CROs and various industry stakeholders – constrained by time and compelled by regulatory compliance – to support broader industry-wide adoption of innovations.
CROs’ adoption of innovative technologies add value throughout the entire development and delivery cycle – from early clinical studies through commercialization and monitoring of new medical products. Sponsors are benefiting from these innovations as are patients, who benefit from having access to new, more individualized treatments earlier.
Key Learning:
- How CROs have leveraged innovation to help accelerate clinical trials
- What technologies have been most impactful?
- What operational shifts needed to occur?
- What are some of the barriers to adopting innovated solutions?
- How innovative trial designs can be offered at scale now.
Speakers Name and Title:
JOHN GABRA
Director of Innovation & Data Science,
IQVIA
NOOLIE GREGORY
VP Decentralized Clinical Trials Operations,
Syneos Health
PHILIPPE ANDRY
VP Data Management and Data Integration
Accelsiors CRO
ALBERTH LARI
Service Delivery Manager CDM
Excelya
ANTOINE MONIN
Clinical Data Manager
Servier for Excelya
Times and Date:
November 17th 2022 9 am CT |10 am ET | 3 pm BST | 4 pm CET
Sponsor:
Oracle
Register Free:
Related to this article
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Trending on PharmExec
1
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
2
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5